Last $8.53 USD
Change Today +0.06 / 0.71%
Volume 399.7K
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

sciclone pharmaceuticals inc (SCLN) Snapshot

Open
$8.50
Previous Close
$8.47
Day High
$8.62
Day Low
$8.42
52 Week High
11/18/14 - $8.89
52 Week Low
04/15/14 - $4.24
Market Cap
433.1M
Average Volume 10 Days
578.4K
EPS TTM
$0.45
Shares Outstanding
50.8M
EX-Date
--
P/E TM
19.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for SCICLONE PHARMACEUTICALS INC (SCLN)

sciclone pharmaceuticals inc (SCLN) Related Bloomberg News

View More Bloomberg News

sciclone pharmaceuticals inc (SCLN) Related Businessweek News

No Related Businessweek News Found

sciclone pharmaceuticals inc (SCLN) Details

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for the treatment of oncology, infectious diseases, and cardiovascular disorders primarily in the People’s Republic of China. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets approximately 10 partnered products in China, including Aggrastat, an interventional cardiology product. The company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Abstral, Loramyc, and ondansetron RapidFilm. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.

570 Employees
Last Reported Date: 03/17/14
Founded in 1989

sciclone pharmaceuticals inc (SCLN) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $550.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $160.4K
Chief Executive Officer of China Operations
Total Annual Compensation: $347.8K
Vice President of Finance and Chief Financial...
Total Annual Compensation: $279.4K
Vice President of Internal Audit
Total Annual Compensation: $273.5K
Compensation as of Fiscal Year 2013.

sciclone pharmaceuticals inc (SCLN) Key Developments

SciClone Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

SciClone Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $34,287,000 compared to $35,226,000 for the same period in 2013. Income from operations was $8,107,000 compared with $29,094,000 a year ago. Income before provision for income tax was $8,246,000 compared with $8,861,000 a year ago. Net income was $7,915,000 or $0.15 per diluted share compared with $8,708,000 or $0.16 per diluted share a year ago. Non-GAAP net income was $8,749,000 or $0.17 per diluted share compared with $9,653,000 or $0.18 per diluted share a year ago. For the nine months, the company's total revenues were $93,365,000 compared to $94,324,000 for the same period in 2013. Income from operations was $22,408,000 compared with $9,614,000 a year ago. Income before provision for income tax was $22,452,000 compared with $12,356,000 a year ago. Net income was $21,689,000 or $0.41 per diluted share compared with $10,928,000 or $0.20 per diluted share a year ago. Non-GAAP net income was $24,298,000 or $0.46 per diluted share compared with $19,136,000 or $0.35 per diluted share a year ago. The company now projects non-GAAP EPS of $0.64 to $0.68. The prior projection announced in August 2014 was non-GAAP EPS of $0.51 to $0.57. The company continues to project revenue of $130 million to $135 million.

SciClone Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 10, 2014

SciClone Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 10, 2014

SciClone Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 10, 2014

SciClone Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $8.53 USD +0.06

SCLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $39.18 USD +1.14
Lannett Co Inc $49.51 USD +1.51
Pernix Therapeutics Holdings Inc $10.66 USD +0.04
Sagent Pharmaceuticals Inc $28.82 USD +0.42
Sarepta Therapeutics Inc $16.81 USD +0.29
View Industry Companies
 

Industry Analysis

SCLN

Industry Average

Valuation SCLN Industry Range
Price/Earnings 21.2x
Price/Sales 3.5x
Price/Book 2.8x
Price/Cash Flow 20.3x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit www.sciclone.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.